We previously demonstrated that the CDK inhibitor PHA848125 - shown to possess a safety profile and a promising activity against thymic carcinoma in a phase I clinical study [32] - inhibited proliferation of A375 cells, at least in part, through down-regulation of PTTG1 [30]. The gene discussed is PTTG1; the disease is thymic carcinoma.